-
Ligand Down 20% Since August 1; What's The Street Thinking?
Wednesday, August 17, 2016 - 3:16pm | 318Ligand Pharmaceuticals Inc. (NASDAQ: LGND) hit a 52-week high of $139.79 at the beginning of August. Since then, the stock has been steadily declining and as of Wednesday was trading for less than $109 per share. The stock is now nearly flat since the start of 2016, but still higher by more...
-
Lemelson Doubles Short Position In Ligand Pharmaceuticals, Says It's Created 'Pyramid Scheme Of Shell Companies'
Sunday, June 7, 2015 - 11:20am | 481Rev. Emmanuel Lemelson was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. Shares of Ligand Pharmaceuticals Inc. (NASDAQ: LGND) hit new 52-week highs of $94.94 on Friday after the company updated the impact from the Viking...
-
This Hedge Fund Manager Says 'Stay Away' From Alibaba
Thursday, January 29, 2015 - 7:31am | 181Lemelson Capital Management Chief Investment Officer Rev. Emmanuel Lemelson warned investors to “stay away from new issues” including Alibaba Group Holding Ltd (NYSE: BABA). Lemelson told Benzinga that the sellers, which includes insiders and investment banks, “have a vested...
-
Lemelson Capital Management CIO Discusses Ligand Pharmaceuticals Prior To Company Issuing Weak Guidance
Tuesday, November 18, 2014 - 4:56pm | 220Ligand Pharmaceuticals Inc. (NASDAQ: LGND) reported on Tuesday it expects its fiscal 2015 earnings per share to be in a range of $2.14 to $2.18, falling short of the consensus estimate of $2.42. The company expects fiscal 2015 sales to be $81 million to $83 million, also below the consensus...
-
Why WWE Network Subscriptions Might Not Be A Big Deal
Wednesday, October 29, 2014 - 1:53pm | 930World Wrestling Entertainment, Inc. (NYSE: WWE) is scheduled to report its third quarter results on October 30 before market open. The company is expected to lose $0.17 per share on revenue of $133.2 million, according to consensus analyst estimates. WWE reported its second quarter results on...